PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15
Media Pack
News

Current Edition

Issue 9 Volume 1

Upcoming Events

SLAS
Bio IT
PEGS Boston
ELRIG Drug Discovery USA
Biotechnology Show 13.02.26
PFS & Injectable drug devices west coast
PFS & Injectable Drug Devices East Cost

Advertisement

A&M Stabtest April 26
Scientific Lab Show
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025
QMB Innovation Centre
Polypure hompage
news

AbbVie keeps up dealmaking pace in neuroscience

Dive Brief: AbbVie announced Friday a new agreement with its longtime partner Gedeon Richter to research and develop dopamine-regulating treatments for neuropsychi...
14 March 2022 news ABBVIE | dealmaking
Continue Reading →
news

FDA approves AbbVie, Pfizer drugs for eczema, creating competition for Sanofi

Dive Brief: The top-selling product for French pharmaceutical giant Sanofi now has two more competitors in the U.S. market, as the Food and Drug Administration on ...
20 January 2022 news ABBVIE | eczema
Continue Reading →
news

Biohaven to seek FDA approval for second migraine drug after study success

While a smaller biotech company, Biohaven has succeeded in a market led by large pharmaceutical firms like Lilly, AbbVie and, in the preventive treatment setting, Amg...
10 December 2021 news ABBVIE | Amgen
Continue Reading →
news

AbbVie’s blockbuster weighed down by safety concerns for a similar Pfizer drug

For years, AbbVie's business has relied on Humira. One of the world's top-selling medicines, Humira brought in close to $20 billion for AbbVie in each of the last thr...
10 December 2021 news ABBVIE | Humira
Continue Reading →
news

Biohaven’s pipeline takes a hit as drug for rare neurological disease falls short in trial

Biohaven has built itself into a nearly $10 billion company on the strength of its migraine drug Nurtec, which surprised Wall Street with second-quarter sales that we...
30 September 2021 news ABBVIE | Amgen
Continue Reading →
news

In a first, FDA approves an ‘interchangeable’ biosimilar for diabetes

The promise of biosimilars — that competition would bring down the prices of complex biological drugs — hasn't materialized in the U.S. in the way many expected. Comp...
5 August 2021 news ABBVIE | Amgen
Continue Reading →
news

Biopharmaceuticals Market Strongly guided by Companies like ABBVIE, AMGEN, BRISTOL

The market is expected to register a CAGR of 8.5% during the forecast period 2018 to 2023. North America dominates the market due to the increasing technological adva...
11 May 2018 news ABBVIE | biopharmaceutical
Continue Reading →
The Bridge 28.01
Newcells 3 June 2024, 15:12
Richter: Wed 23 October 2024, 09:03
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025
Crown Bioscience 08.09.2025
Aseptic Tech
PharmExcel
IBI-white.png

International Biopharmaceutical Industry

IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.

Facebook Linkedin
Bio Pharmaceutical Media © 2026, All Rights Reserved – Powered by Teksyte